# Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

> **NCT04548271** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 25 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT04548271
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2022-10
- **Final completion:** 2023-10
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2020-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04548271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04548271, "Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04548271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*